Ypsomed announced on Wednesday that Michel would not stand for re-election as President at the General Assembly on June 29.
Gilbert Achermann succeeds Michel as Chairman of the Board of Directors. The Board of Directors proposes him for election. Achermann has been on the board since 2020 and is also President of the dental implant manufacturer Straumann, a member of the Board of Directors of the Julius Baer Group and part of the executive bodies of the Lausanne Management Institute IMD and the Swiss Medtech industry association.
“With full conviction I have come to the conclusion that now is the best time to pass on the baton,” Willy Michel is quoted as saying in the message. The company has developed further in recent years and is ideally positioned to face the major challenges in the healthcare sector.
“Although saying goodbye is difficult for me, I know that the course has been set for Ypsomed’s successful future,” added Willy Michel. In 1984, together with his brother, Michel founded Disetronic, a company specializing in infusion systems and injection systems. After the sale of the infusion business to Roche, the company was renamed Ypsomed in 2004. Today, Ypsomed employs around 1,900 people and achieves annual sales of a good 400 million Swiss francs.
The Michel family is the main shareholder with around 74 percent of the share capital. It is ensured that the family will continue to be well represented in the Ypsomed management: At the General Assembly, Simon Michel, Willy Michel’s son, is to be elected to the Board of Directors. Simon Michel has been working at Ypsomed since 2006. He took over the management from his father as CEO in 2014.